Inhibrx Biosciences, Inc. INBX Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)?
- Inhibrx Biosciences, Inc. (INBX) reported other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) of $186K in Q1 2026.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) has grown at a -46.0% compound annual growth rate (CAGR), from $607K to $177K.